SANGAMO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
SANGAMO THERAPEUTICS, INC. (SGMOQ) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding of $2.37 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding · last filed 2026-03-30
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $2.37M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $11.24M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $3.29M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $16.47M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding |
|---|---|
| 2025-12-31 | $2.37M 10-K · filed 2026-03-30 |
| 2024-12-31 | $11.24M 10-K · filed 2025-03-17 |
| 2023-12-31 | $3.29M 10-K · filed 2024-03-13 |
| 2022-12-31 | $16.47M 10-K · filed 2023-02-23 |
| 2021-12-31 | $23.55M 10-K · filed 2022-02-24 |
| 2020-12-31 | $41.69M 10-K · filed 2021-02-24 |
| 2019-12-31 | $7.22M 10-K · filed 2020-02-28 |
| 2018-12-31 | $3.71M 10-K · filed 2019-03-01 |
| 2017-12-31 | $1.31M 10-K · filed 2018-03-01 |
| 2016-12-31 | $982.00K 10-K · filed 2017-02-28 |
| 2015-12-31 | $7.58M 10-K · filed 2016-02-18 |
| 2014-12-31 | $13.68M 10-K · filed 2015-02-25 |